StargardtDisease,RareDisease,Ophthalmology

Mashup Score: 0

Gildeuretinol Halts Stargardt Progression in Interim TEASE-3 Results - 9 hour(s) ago

Additional TEASE-3 participants who completed 24 months of gildeuretinol therapy reported no progression in Stargardt disease, including stable visual acuity.

Source: www.hcplive.com

Categories: General Medicine News, General HCPs

Tweet Tweets with this article
- MDMagazine
  
  Once-daily oral gildeuretinol halted disease progression in additional patients with early-stage Stargardt disease, according to positive interim data from the TEASE-3 clinical trial. 🔗 https://t.co/xXXz9LFTc6 #StargardtDisease #RareDisease #Ophthalmology https://t.co/gAvLBoG9rQ